

Five-year outcomes with delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD): A Phase 1/2a study

JR Mendell,^{1,2}* Z Sahenk,^{1,2} LP Lowes,^{1,2} NF Reash,¹ MA lammarino,¹ LN Alfano,¹ JE Signorovitch,³ J Jin,⁴ P Gao,⁴ S Mason,^{4†} JS Elkins,⁴ LR Rodino-Klapac⁴

¹Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH, USA; ²The Ohio State University, Columbus, OH, USA; ³Analysis Group, Boston, MA, USA; ⁴Sarepta Therapeutics, Inc, Cambridge, MA, USA.

*Employed at Nationwide Children's Hospital and The Ohio State University at the time of this study; currently employed by Sarepta Therapeutics, Inc.

⁺Presenting on behalf of the authors (email address: medinfo@sarepta.com)



The 5-year outcomes from Study 101 support the long-term, manageable safety profile and demonstrate stabilisation or slowing of DMD disease progression with delandistrogene moxeparvovec, with a profound divergence from natural history.

Introduction

- Delandistrogene moxeparvovec is an rAAVrh74 vector-based gene transfer therapy that delivers a transgene encoding delandistrogene moxeparvovec micro-dystrophin, an engineered, functional form of dystrophin shown to stabilise or slow disease progression in DMD.^{1–4}
- It is approved in the US and in other select countries.^{5–11}

Results

- **Demographics and baseline patient characteristics**
- Demographics and baseline characteristics of the patients have been published previously.³
 - EC cohort baseline characteristics were comparable with those of patients in the delandistrogene moxeparvovec group.¹³
- At 5 years post-infusion, the mean (range) age of patients was 10.20 (9.07–11.12) years.

Primary endpoint: Safety

• AEs occurring at Years 1 and 4 post-treatment have been reported.^{3,13} Overall, 75 AEs were reported (most occurred ≤70 days post-infusion).

Conclusions



Over the 5-year follow-up period, there were no new safety signals reported after the initial 70 days post-infusion, supporting the manageable and consistent safety profile of delandistrogene moxeparvovec.




Study 101 (SRP-9001-101; NCT03375164) is a Phase 1/2a, single-dose, open-label clinical trial to evaluate the safety of delandistrogene moxeparvovec in ambulatory patients with DMD (\geq 4 to <8 years old).³

Objective


- We provide a 5-year update on long-term safety and functional data from four patients treated with delandistrogene moxeparvovec.
- To contextualise functional outcomes, post hoc analyses comparing the 5-year data from Study 101 with a propensity-score-weighted EC cohort and their natural history predictions (NSAA total score) were conducted.

Methods



- Eighteen TR-TEAEs were reported (all mild or moderate).
- The most common were vomiting and increased liver enzymes (all resolved).
- There were no SAEs, clinically significant complement-mediated AEs, study discontinuations or deaths.

Figure 2. Change from baseline to year 5 in NSAA total score in the delandistrogene moxeparvovec group versus EC cohort



- Delandistrogene moxeparvovec-treated patients showed a sustained increase in NSAA total score over 5 years, with a statistically significant and clinically meaningful difference at Year 5 compared with the EC cohort (Figure 2).
- All delandistrogene moxeparvovec-treated patients remained ambulant throughout the study duration whilst four patients in the EC cohort experienced loss of ambulation at 8.4–11.6 years old (between 18 and 54 months post-adjusted baseline).

- Long-term outcomes from this study support the biological role of functional dystrophin and indicate that delandistrogene moxeparvovec stabilises or slows DMD disease progression with an increase in divergence from natural history over time.
- There was a statistically significant and clinically meaningful difference in TTR from the floor in the delandistrogene moxeparvovec-treated patients versus the EC cohort at Year 5.
- 10MWR time was maintained amongst delandistrogene moxeparvovec-treated patients over 5 years, demonstrating a clinically meaningful difference versus the EC cohort at Year 5.
- The NSAA findings were further corroborated using an independent model-based approach (cTAP) that supported the increase in divergence in disease progression from natural history over time with treatment.

*All patients received one IV infusion in the peripheral limb vein at the dose 2.0×10¹⁴ vg/kg determined by supercoiled qPCR method (1.33×10¹⁴ vg/kg linear qPCR equivalent), and prednisone (1 mg/kg/day) 1 day pre- to 30 days post-gene therapy delivery.

Primary outcome measure:

• Safety based on the number of patients with AEs.


Key additional outcome measures:


Change from baseline in NSAA and TFTs (including TTR from the floor and 10MWR).

Propensity-score-weighted EC cohort

- In this post hoc analysis, delandistrogene moxeparvovec-treated patients (N=4) at 5 years were compared with a propensity score-weighted EC cohort (n=17) at 4.5 years, which included patients from the FOR-DMD study (NCT01603407).
- FOR-DMD was an international, multicentre study comparing three corticosteroid regimens widely used for DMD.¹²

Figure 3. Change from baseline to Year 5 in TTR from the floor (sec) and 10MWR (sec) in the delandistrogene moxeparvovec group versus EC cohort





ACKNOWLEDGMENTS AND DISCLOSURES

The authors thank the patients and their families for their participation in Study 101 (SRP-9001-101), as well as the investigators and trial staff involved in Study 101. Study 101 was sponsored and funded by Sarepta Therapeutics, Inc., Cambridge, MA, USA. Medical writing and editorial assistance was provided by Ayesha Babar, MSc, of Nucleus Global in accordance with Good Publication Practice (GPP) 2022 guidelines (<u>https://www.ismpp.org/gpp-2022</u>) and was funded by Sarepta Therapeutics, Inc., Cambridge, MA, USA. JRM received study funding from Sarepta Therapeutics while at Nationwide Children's Hospital at the time of the study and is currently an employee of Sarepta Therapeutics. In addition, he is a co-inventor of AAVrh74.MHCK7.micro-dys technology. ZS has received grant support from Sarepta Therapeutics and the Parent Project Muscular Dystrophy. LPL reports serving on an advisory board and receiving salary support from Sarepta Therapeutics through Nationwide Children's Hospital to support training and quality control activities for their ongoing clinical trials and licensing fees for natural history data. NFR reports receiving salary support from Sarepta Therapeutics for Clinical Evaluator training for ongoing and upcoming clinical trials. MAI has nothing to disclose. LNA reports receiving salary support from Sarepta Therapeutics through Nationwide Children's Hospital to support training and quality control activities for their ongoing clinical trials. JES is an employee of Analysis Group Inc., which has received research funding from Sarepta Therapeutics. JJ, PG, SM and JSE are employees of Sarepta Therapeutics and may have stock options. LRR-K is an employee of Sarepta Therapeutics and may have stock options. In addition, she is a co-inventor of AAVrh74.MHCK7.micro-dys technology.

ABBREVIATIONS

10MWR, 10-metre Walk/Run; rAAVrh74, recombinant adeno-associated virus rhesus isolate serotype 74; AE, adverse event; cTAP, collaborative Trajectory Analysis Project; DMD, Duchenne muscular dystrophy; EC, external control; FOR-DMD, Finding the Optimum Regimen for Duchenne Muscular Dystrophy; IV, intravenous; LSM, least squares mean; NSAA, North Star Ambulatory Assessment; qPCR, quantitative polymerase chain reaction; SAE, serious AE; SD, standard deviation; SE, standard error; TFT, timed function test; TR-TEAE, treatment-related treatment-emergent AE; TTR, Time to Rise; vg, vector genome.

REFERENCES

1. Asher DR, et al. *Expert Opin Biol Ther*. 2020; 20:263–274; 2. Zheng C and Baum BJ. Methods Mol Biol. 2008; 434:205–219; 3. Mendell JR, et al. JAMA Neurol. 2020; 77:1122–1131; 4. Mendell JR, et al. Presented at MDA 2024; M164; 5. US Food and Drug Administration. ELEVIDYS[®] Highlights of prescribing information. https://www.fda.gov/media/169679/download (Accessed October 2024); 6. Qatar Ministry of Public Health Update, 27 September 2023. Roche data on file; 7. UAE Ministry of Health & Prevention. https://mohap.gov.ae/en/services/registeredmedical-product-directory (Accessed October 2024); 8. Kuwait Ministry of Health Update, 19 February 2024. Roche data on file; 9. National Health Regulatory Authority Bahrain https://www.nhra.bh/Departments/PPR/ (Accessed October 2024); 10. Ministry of Health Oman, Registration Certificate, 25 March 2024. Roche data on file; 11. Ministry of Health Israel, Registration Certificate. 27 June 2024. Roche data on file; 12. FOR-DMD. https://for-dmd.org/en/ (Accessed October 2024); 13. Mendell JR, et al. Muscle Nerve. 2024;69:93–98.

• The EC cohort has 5 years of follow-up data. To match inclusion criteria for Study 101, which required ≥12 weeks of stable dose or dose equivalent of corticosteroids before baseline, the new baseline resulted in a 4.5-year follow-up time. • Propensity-score weighting incorporated baseline factors known to be prognostic of functional trajectories in DMD, namely age, NSAA total score, TTR from the floor and 10MWR, to ensure baseline comparability on these factors between the delandistrogene moxeparvovec and EC groups, as described previously.¹³

Predictive controls

Expected NSAA total score trajectories without delandistrogene moxeparvovec treatment were predicted for patients with matched baseline prognostic factors (including age and motor function) as those treated in Study 101 using a previously developed model (cTAP).

moxeparvovec	4	4	3	4	4	4	Delandistrogene moxeparvovec (N=4)
EC cohort	17	17	17	17	17 16		EC cohort (n=16)

• There was a statistically significant and clinically meaningful difference in TTR from the floor in the delandistrogene moxeparvovec-treated patients versus the EC cohort at Year 5 (Figure 3, top panel). 10MWR time was maintained amongst delandistrogene moxeparvovec-treated patients over 5 years, demonstrating a clinically meaningful difference versus the EC cohort at Year 5 (Figure 3, bottom panel).


Figure 4. NSAA total score of individual delandistrogene moxeparvovec-treated patients versus their natural history predictions (cTAP model)

[.] Delandistrogene moxeparvovec 🛛 📃 Mean prediction band (95%)

 Δ treated patients vs. EC cohort:

LSM (SE): -2.5 (1.8) seconds;

P=0.1869



cTAP modelling showed an increase in divergence of NSAA total score trajectory of delandistrogene moxeparvovec-treated patients versus their natural history predictions over 5 years of follow-up (Figure 4).

SCAN THE QR CODE

The QR code is intended to provide scientific information for individual reference, and the information should not be altered or reproduced in any way.



https://www.sareptacongresshub.com/wms2024/Study101/ Mason#pdf

> **Presented at The 29th Annual Congress** of the World Muscle Society (WMS);

8–12 October 2024; Prague, Czechia